MARSHALL & POPP, LLC

Lobbying for CSL BEHRING · Biopharmaceutical manufacturer.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Pennsylvania · House · Senate · $50,000.00 income · posted Jan 16, 2026

Lobbying activity 2

Pharmacy

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).

Trade (domestic/foreign)

Issues related to tariff and trade policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.